Access
To read this story in full you will need to login or make a payment (see right).
Community Corner
Nature Medicine 15, 615 (2009)
doi:10.1038/nm0609-615
Compound clamps down on prostate cancer
Most individuals with metastatic prostate cancer develop resistance to standard treatments, which antagonize the action of growth-promoting androgens. The origins of such 'castration-resistant' tumors have been traced in part to increases in expression of the androgen receptor and to shortcomings in receptor-blocking drugs, which can even act as agonists.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Prostate cancer PSA as an intermediate end point in clinical trialsNature Reviews Urology News and Views (01 Sep 2009)
